Accordingly, the discovery of novel bioactive compounds capable of targeting multiple cancer-relevant pathways has become an attractive and promising strategy for cancer treatment.4 In the context of cancer hallmarks, different targets have been incorporated with distinct aspects in tumor growth and survival, including tubulin-β, aromatase, and α-glucosidase. The gene discussed is CYP19A1; the disease is neoplasm.